Brexit No Certain Thing For European Medtech Groups Desperate To Plan Futures
Medtech stakeholders were reminded at the UK's largest regulatory forum that, for business in general, and medical technology manufacturers in particular, those willing to make the best of Brexit are still having to work in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.
You may also be interested in...
A new "rolling plan" provides deadlines for implementing actions, and other efforts, that are necessary to get the new EU Medical Device and IVD Regulations off the ground.
The UK medtech sector is desperate for substantive information about what is expected of them and how they should proceed as the threat of a no-deal Brexit lingers, says Richard Phillips, who runs policy operations for trade group ABHI. Will the October EU Council meeting provide answers?
Royal Philips closed out the first year of COVID-19 with 7% revenue growth in the fourth quarter. CEO Frans van Houten says low single digit growth is the target for fiscal 2021.